Clinical trial · Observational
Effect of Different Treatments on the Prognosis of Early Cervical Cancer: A Multicenter, Prospective, Real-world Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe the effects of different treatments on the oncological outcome and complications of early cervical cancer (2018 FIGO stage IA1 with lymphovascular space invasion and IA2-IIA2 cervical cancer). This study prospectively collecting enrolled cervical cancer patients clinical data and outcome from June 2020 to June 2025. (Classification factors: preoperative neoadjuvant treatment , surgical approach, type of hysterectomy, whether to receive radiochemotherapy) . This study is an observational study, and segmented analysis according to different treatment methods.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| clinical routine treatments | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival (OS)
- timeFrame
- 60 months from primary treatment
- description
- Overall survival was defined as the period from initial treatment until cervical cancer related death.
- measure
- disease-free survival (DFS)
- timeFrame
- 60 months from primary treatment
- description
- Tumor-free survival was defined as the period from initial treatment until the recurrence or the date of last follow-up.
Secondary outcomes (6)
- measure
- Patterns of recurrence
- timeFrame
- 60 months from primary treatment
- description
- date and localization of 1st recurrence as confirmed histologically
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed primary adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix. 2. Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), FIGO 2018 stage IA2 to IIA2. 3. Underwent radical hysterectomy or radiochemotherapy. 4. ECOG Performance Status of 0 or 1. Exclusion Criteria: 1. Life expectancy is less than 6 months 2. No prior malignancy 3. ECOG Performance Status of 2 to 5.
References
Publications (0)
Data not yet available